Merck&Co reports GAAP EPS of $1.12 in Q1, up 315% YoY

Tuesday, 30. April 2019 12:47

American pharmaceutical giant Merck & Co. Inc. reported on Tuesday its GAAP earnings per share for the first quarter of 2019 stood at $1.12, increasing 315% on an annual basis. The company's worldwide sales amounted to $10.8 billion, up 8% compared to the same time period last year and its net income reached a figure of $2.91 billion, marking an almost 300% increase year over year.

The pharmaceutical company continued to advance the development programs for KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy; Lynparza (olaparib), a PARP inhibitor being co-developed and co-commercialized with AstraZeneca; and Lenvima (lenvatinib mesylate), an orally available tyrosine kinase inhibitor being co-developed and co-commercialized with Eisai Co., Ltd. (Eisai).

"Our strong start to 2019, with double-digit sales and EPS growth in the first quarter, demonstrates our execution across all aspects of our business and the strength of our key growth pillars, including oncology and vaccines. Our investments in research and development are paying off, and we are confident in our science-driven strategy, growth prospects and ability to sustainably deliver value to patients and shareholders." Merck Chief Executive Officer Kenneth C. Frazier said.

Merck shares were 2.74% in the green during the premarket trading.

Related Links: Merck & Co. Inc.
Breaking the News / MD